Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study.
electronic headache diary
erenumab
migraine
real-world data
responder
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
21
06
2021
accepted:
19
08
2021
pubmed:
24
8
2021
medline:
2
4
2022
entrez:
23
8
2021
Statut:
ppublish
Résumé
New prophylactics for migraine, targeting calcitonin gene-related peptide (CGRP), have recently emerged. Real-world data are important for a comprehensive understanding of treatment response. We assessed the consistency of response to erenumab, a monoclonal CGRP receptor antibody, in a real-world setting, in order to determine which patients may be considered responders in clinical practice. All erenumab-treated patients (n = 100) completed a time-locked daily electronic diary, and an automated algorithm was used to monitor treatment response. Monthly migraine days (MMD), non-migrainous headache days, days of acute medication use (MAMD), well-being and coping with pain were assessed for a 6-month period. The primary outcome was reduction in MMD compared to baseline. The numbers of MMD and MAMD decreased in all months, in both episodic and chronic migraine patients, compared to baseline (p < 0.001), while general well-being (p < 0.001) and coping with pain (p < 0.001) also improved. Of all patients, 36% had an MMD reduction of ≥50% in ≥3/6 months, and 6% had such a reduction in all 6 months. For a ≥30% MMD reduction, the figures were 60% and 24%, respectively. Almost 90% of patients with an average MMD reduction of ≥30% over the first 3 months had a sustained response in the last 3 months. In addition, 20% of patients without an initial response (average <30%), had a delayed response (average ≥30%) in the last 3 months. Erenumab was effective in migraine patients who were highly refractory to previous prophylactics. As a practical guideline, we propose that treatment be continued for at least 6 months and that patients with a ≥30% MMD reduction in at least half of the treatment period should be considered to be responders.
Sections du résumé
BACKGROUND AND PURPOSE
New prophylactics for migraine, targeting calcitonin gene-related peptide (CGRP), have recently emerged. Real-world data are important for a comprehensive understanding of treatment response. We assessed the consistency of response to erenumab, a monoclonal CGRP receptor antibody, in a real-world setting, in order to determine which patients may be considered responders in clinical practice.
METHODS
All erenumab-treated patients (n = 100) completed a time-locked daily electronic diary, and an automated algorithm was used to monitor treatment response. Monthly migraine days (MMD), non-migrainous headache days, days of acute medication use (MAMD), well-being and coping with pain were assessed for a 6-month period. The primary outcome was reduction in MMD compared to baseline.
RESULTS
The numbers of MMD and MAMD decreased in all months, in both episodic and chronic migraine patients, compared to baseline (p < 0.001), while general well-being (p < 0.001) and coping with pain (p < 0.001) also improved. Of all patients, 36% had an MMD reduction of ≥50% in ≥3/6 months, and 6% had such a reduction in all 6 months. For a ≥30% MMD reduction, the figures were 60% and 24%, respectively. Almost 90% of patients with an average MMD reduction of ≥30% over the first 3 months had a sustained response in the last 3 months. In addition, 20% of patients without an initial response (average <30%), had a delayed response (average ≥30%) in the last 3 months.
CONCLUSION
Erenumab was effective in migraine patients who were highly refractory to previous prophylactics. As a practical guideline, we propose that treatment be continued for at least 6 months and that patients with a ≥30% MMD reduction in at least half of the treatment period should be considered to be responders.
Identifiants
pubmed: 34424593
doi: 10.1111/ene.15075
pmc: PMC9291504
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Calcitonin Gene-Related Peptide Receptor Antagonists
0
Receptors, Calcitonin Gene-Related Peptide
0
erenumab
I5I8VB78VT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4194-4203Informations de copyright
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Cephalalgia. 2019 Mar;39(3):445-458
pubmed: 30661365
J Headache Pain. 2020 Jul 3;21(1):84
pubmed: 32620151
Cephalalgia. 2018 Jul;38(8):1442-1454
pubmed: 29848108
Lancet Neurol. 2020 Oct;19(10):814-825
pubmed: 32949542
J Headache Pain. 2020 Apr 07;21(1):32
pubmed: 32264820
Neurology. 2020 Aug 4;95(5):e469-e479
pubmed: 32636324
Cephalalgia. 2018 Apr;38(5):815-832
pubmed: 29504482
Cephalalgia. 2021 Oct;41(11-12):1161-1171
pubmed: 33938248
Am J Physiol. 1989 Mar;256(3 Pt 1):G546-52
pubmed: 2564254
Cephalalgia. 2018 May;38(6):1026-1037
pubmed: 29471679
J Headache Pain. 2017 Oct 4;18(1):101
pubmed: 28980171
N Engl J Med. 2017 Nov 30;377(22):2123-2132
pubmed: 29171821
Lancet. 2018 Nov 24;392(10161):2280-2287
pubmed: 30360965
Neurology. 2020 Aug 18;95(7):e878-e888
pubmed: 32747522
Health Qual Life Outcomes. 2014 Aug 01;12:117
pubmed: 25080874
Eur J Neurol. 2021 Dec;28(12):4194-4203
pubmed: 34424593
J Headache Pain. 2019 Jan 16;20(1):6
pubmed: 30651064
Curr Opin Neurol. 2016 Jun;29(3):331-6
pubmed: 26926672
Lancet. 2020 Jul 11;396(10244):95-96
pubmed: 32653068
Cephalalgia. 2016 Feb;36(2):122-30
pubmed: 25903762
Cephalalgia. 2020 Sep;40(10):1026-1044
pubmed: 32722936
Front Neurol. 2020 May 28;11:417
pubmed: 32547474
Lancet. 2019 Sep 21;394(10203):1030-1040
pubmed: 31427046
Continuum (Minneap Minn). 2015 Aug;21(4 Headache):973-89
pubmed: 26252585